Printer Friendly

Interim Analysis Supports Continuation of Phase 3 Trial Of Tifacogin; Pivotal Study of Chiron Drug for Treatment of Severe Community-Acquired Pneumonia Proceeds.

EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ:CHIR) today announced that an independent Data Monitoring Committee (DMC) has recommended the continuation of Chiron's CAPTIVATE study, an ongoing Phase 3 clinical trial of tifacogin for the treatment of patients with severe community-acquired pneumonia. The DMC made its recommendation following a planned interim analysis of clinical data from the study. The study data remains blinded to Chiron, and detailed analysis will not be available until the trial has been completed. No safety concerns were identified by the committee, confirming safety assessments conducted when patient enrollment reached 300 and again at 600.

"We appreciate the careful analysis conducted by the committee and their assessment of the study data on tifacogin," said Stephen Dilly, M.D., Ph.D., chief medical officer of Chiron BioPharmaceuticals. "We look forward to a final analysis of the study data."

The study is expected to enroll 2,100 patients in 200 centers in 19 countries worldwide, and enrollment is expected to be completed in the first half of 2007. The primary endpoint of the study is reduction in mortality at 28 days.

About Tifacogin

Tifacogin, a recombinant form of tissue-factor pathway inhibitor (TFPI), is an investigational drug being evaluated for the treatment of severe community-acquired pneumonia (CAP). Increased expression of tissue factor, a protein, occurs in the lungs of pneumonia patients, where it is believed to directly contribute to activation of blood coagulation and inflammation. Tifacogin interferes with these activities of tissue factor, and the balance of tissue factor and TFPI levels is a key mechanism for the body's control of coagulation. Naturally occurring TFPI levels are not sufficient to compensate for the increase in tissue factor associated with lung infection. Therapeutic administration of tifacogin to restore this balance may be an effective treatment for severe CAP.

About Severe Community-Acquired Pneumonia

Severe community-acquired pneumonia (CAP) is defined as pneumonia contracted outside of a hospital setting that requires the patient's admission to an intensive-care unit. Severe CAP affects approximately 300,000 patients in the United States annually. Approximately 30 percent of patients with severe CAP die. Current therapy includes routine antibiotics and supportive care. However, despite improvements in antibiotic treatment, mortality rates associated with severe CAP have remained approximately constant for the past 50 years. No adjunctive drugs are currently approved for the reduction of mortality in severe CAP.

About Chiron

Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information about Chiron, please visit www.chiron.com.

This news release contains forward-looking statements, including statements regarding the development of tifacogin, results from the CAPTIVATE clinical trial, marketing approval for tifacogin and the market for products to treat severe community-acquired pneumonia, that involve risks and uncertainties and are subject to change. Forward-looking statements often address our expected future performance and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." A discussion of the company's operations and financial condition, including factors that may affect its business and future prospects that could cause actual results and developments to differ materially from those expressed or implied by forward-looking statements, is contained in documents the company has filed with the SEC, including the Form 10-K for the year ended December 31, 2004, and the Form 10-Q for the quarter ended September 30, 2005, and will be contained in all subsequent periodic filings made with the SEC. These documents identify important factors that could cause the company's actual performance to differ from current expectations, including, among others, the outcome of clinical trials, regulatory review and approvals, manufacturing capabilities, intellectual property protections and defenses, litigation, and marketing effectiveness. In addition, the company may engage in business opportunities, the successful completion of which is subject to certain risks, including approval by Novartis AG, regulatory approvals, and the integration of operations.

Chiron does not undertake an obligation to update the forward-looking information the company is giving today.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 19, 2005
Words:672
Previous Article:Horne Engineering Awarded Contracts To Provide Technical and Management Support to Customs and Border Protection; Pending Award for Additional Work...
Next Article:RadarSync Removes Registration Process from Popular PC Update and Maintenance Service.
Topics:


Related Articles
Drug spray strikes out in severe pneumonia.
LORUS' VIRULIZIN EFFECTIVE AGAINST PANCREATIC TUMORS.
Quinolone safety and efficacy more important than potency.
Data and Safety Monitoring Board Recommends That CancerVax Continue Canvaxin Phase 3 Clinical Trial for Stage III Melanoma.
Quinolone safety and efficacy.
ValueAct Capital Refuses to Meet with Chiron Directors Except to Discuss Ways to Increase Shareholder Value beyond $45.
BASILEA REPORTS 92% CLINICAL CURE RATES FOR CEFTOBIPROLE.
FDA CLEARS BIOMS MEDICAL FOR PHASE III MULTIPLE SCLEROSIS.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters